CompletedPhase 1NCT04015648
Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)
Studying Zika virus disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oxford
- Principal Investigator
- Adrian V Hill, DPhill FRCPCentre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
- Intervention
- ChAdOx1 Zika(biological)
- Enrollment
- 24 target
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2019 – 2022
Study locations (1)
- CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04015648 on ClinicalTrials.govOther trials for Zika virus disease
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT04398901Neurodevelopmental Outcomes in ZIKV-Exposed ChildrenChildren's National Research Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03037164INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsCerus Corporation
- RECRUITINGNCT01386424Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsNational Institute of Allergy and Infectious Diseases (NIAID)